O-03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH

• TELEN M.,
• BROWN R.,
• HAGAR R.,
• IDOWU M.,
• OSUNKWO I.,
• KALFA T.,
• KUYPERS F.,
• GEIB J.,
• SCHROEDER P.,
• WU E.,
• KELLY P.,
• SARAF S.

Affiliations

TELEN M.

1 Duke University School of Medicine, Durham, UNITED STATES

BROWN R.

2 Children’s Healthcare of Atlanta, Atlanta, UNITED STATES

HAGAR R.

3 UCSF Benioff Children’s Hospital San Francisco, Oakland, UNITED STATES

IDOWU M.

4 UTHealth McGovern Medical School, Houston, UNITED STATES

OSUNKWO I.

5 Levine Cancer Institute, Atrium Health, Charlotte, UNITED STATES

KALFA T.

6 Cincinnati Children’s Hospital Medical Center, Cincinnati, UNITED STATES

KUYPERS F.

7 University of California, San Francisco, UNITED STATES

GEIB J.

8 Forma Therapeutics, Inc., Watertown, UNITED STATES

SCHROEDER P.

8 Forma Therapeutics, Inc., Watertown, UNITED STATES

WU E.

8 Forma Therapeutics, Inc., Watertown, UNITED STATES

KELLY P.

8 Forma Therapeutics, Inc., Watertown, UNITED STATES

SARAF S.

9 University of Illinois at Chicago, Chicago, UNITED STATES